OPTIC Key Takeaways

Key Takeaways (KT) are one-page summaries of published research tailored for policymakers. Choose a topic below to see related KTs.

Note: Choosing the links below will download the KT as a PDF. If you prefer to view the KT in a new browser tab:

• PC users - right click on the Key Takeaway link and choose "Open link in new tab"
• Mac users - Press and hold the control key while clicking on the KT link and choose "Open link in new tab"

Geographic and Population Variation in Health Care Use

• Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality
• County Data Highlight Links between Neonatal Opioid Withdrawal Syndrome and Placement of Infants in Foster Care
• Do Policies Related to Substance Use in Pregnancy Affect Rates of Neonatal Abstinence Syndrome?
• Examining Access to Buprenorphine-Waivered Prescribers in U.S. Counties
• Growing Racial/Ethnic Disparities in Buprenorphine Distribution in the United States, 2007–2017
• Has Expanded Access to Buprenorphine Expanded Treatment for Medicaid Enrollees?
• How Many Patients Do Waivered Buprenorphine Prescribers Treat?
• How Pregnancy and Insurance Status Affect Access to Treatment for Opioid Use Disorder
• Increasing Access to Buprenorphine for Treating Opioid Use Disorder
• No State Adopted a Comprehensive Policy Package to Expand Access to OUD Treatment During COVID
• Opioid Crisis Has Disproportionately Affected Individuals Without Any College Education
• The Social Context of Neonatal Abstinence Syndrome

Maternal and Child Health

• County Data Highlight Links between Neonatal Opioid Withdrawal Syndrome and Placement of Infants in Foster Care
• Do Policies Related to Substance Use in Pregnancy Affect Rates of Neonatal Abstinence Syndrome?
• How Pregnancy and Insurance Status Affect Access to Treatment for Opioid Use Disorder
• The Shift to Illicit Opioids Explains About Half of the Growth in Child Suicide Rates Since 2010
• The Social Context of Neonatal Abstinence Syndrome

Naloxone

• Are Individuals in Long-Term Opioid Therapy Receiving Naloxone?
• Details of Naloxone Access Laws Make a Difference
• How Effective and Implementable Are State-Level Naloxone Access Policies?
• Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010–2018
• Who Receives Naloxone from Emergency Medical Services?

Opioid Prescribing

• Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality
• Are Individuals in Long-Term Opioid Therapy Receiving Naloxone?
• Cascading Effects of the Reformulation of OxyContin
• The Effect of State Policies on Rates of High-Risk Prescribing of an Initial Opioid Analgesic
• Greater Prevalence of Illicit Opioids Reduces Labor Supply and Increases Claims for Disability Insurance
• Growing Racial/Ethnic Disparities in Buprenorphine Distribution in the United States, 2007–2017
• Has Expanded Access to Buprenorphine Expanded Treatment for Medicaid Enrollees?
• High-Risk Prescribing to Medicaid Enrollees Receiving Opioids for Pain Relief
• How Many Patients Do Waivered Buprenorphine Prescribers Treat?
• How Pregnancy and Insurance Status Affect Access to Treatment for Opioid Use Disorder
• How Prescription Drug Monitoring Programs Affect Opioid Utilization Among Medicare Beneficiaries
• Increasing Access to Buprenorphine for Treating Opioid Use Disorder
• Just Increasing the Number of Waivered Providers Won’t Increase Equity Access to Buprenorphine
• Medicaid Expansion May be the Most Effective Policy for Increasing the Breadth of Networks for Buprenorphine Providers
• Rate of High-Risk Opioid Prescribing from the Same Doctor Differs Across Medicaid, Commercial, and Self-Pay Patients

Opioid Use Disorder Treatment

• Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality
• Antidepression Treatment Lowers the Risk of Adverse Outcomes for Individuals Receiving Opioids for Chronic Pain
• Are Individuals in Long-Term Opioid Therapy Receiving Naloxone?
• Buprenorphine Providers in Many States Require Insured Women to Pay Cash for Opioid Use Disorder Treatment
• Do Policies Related to Substance Use in Pregnancy Affect Rates of Neonatal Abstinence Syndrome?
• Examining Access to Buprenorphine-Waivered Prescribers in U.S. Counties
• Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder
• Greater Attention to Professional Education and Clinician Knowledge Can Increase Access to Treatment for Opioid Use Disorder
• Growing Racial/Ethnic Disparities in Buprenorphine Distribution in the United States, 2007–2017
• Has Expanded Access to Buprenorphine Expanded Treatment for Medicaid Enrollees?
• How Effective and Implementable Are State-Level Naloxone Access Policies?
• How Many Patients Do Waivered Buprenorphine Prescribers Treat?
• How Pregnancy and Insurance Status Affect Access to Treatment for Opioid Use Disorder
• Increase Access to Buprenorphine by Supporting the Most Active Prescribers
• Increasing Access to Buprenorphine for Treating Opioid Use Disorder
• No State Adopted a Comprehensive Policy Package to Expand Access to OUD Treatment During COVID
• Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020
• Who Receives Naloxone from Emergency Medical Services?